Medtronic has received CE mark approval in the European Union for its Cobalt and Crome implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).
The company, which is based in Dublin, announced the news Jan. 30. According to a release, the newest generations of Medtronic’s implantable heart devices include a handful of “smart” features, including Intrinsic ATP, an automated algorithm that adapts to a patient’s irregular heart rhythms and tries to reset them with pacing therapy, and the EffectivCRT and AdaptivCRT algorithms, which adjust therapy according to minute-by-minute assessments of a patient’s heart rhythm.
“Cobalt and Crome heart devices deliver the opportunity of a personalized approach to defibrillator therapy, demonstrating how far we have come in this field,” Klaus Witte, MD, of the University of Leeds in the U.K., said in the release. “Moreover, these devices offer seamless patient care through their ability to transmit device and patient data via smartphone or tablet.”
Medtronic is reportedly launching its TriageHF tech in conjunction with the Cobalt and Crome platforms. TriageHF evaluates patients’ heart failure risk through an automatic tool that tracks and identifies any changes in a patient’s health status that could lead to worsening heart failure or hospitalization.
“These advancements will help physicians respond to patients’ individual needs through informed clinical decision-making, potentially improving the outcomes of patients around the world,” said Rob Kowal, MD, PhD, CMO of the Cardiac Rhythm and Heart Failure division of Medtronic.